Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis

BACKGROUND: Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports to improve clinical outcomes by counteracting the inflammatory and thrombotic consequences of severe sepsis. Controversy exists around the clinical benefits of this drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Vania, Brophy, James M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929064/
https://www.ncbi.nlm.nih.gov/pubmed/17592639
http://dx.doi.org/10.1186/1471-2253-7-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929064/
https://www.ncbi.nlm.nih.gov/pubmed/17592639
http://dx.doi.org/10.1186/1471-2253-7-5

Ejemplares similares